On March 25, 2026, the FDA approved Lifyorli (relacorilant), made by Corcept Therapeutics, in combination with Abraxane (nab-paclitaxel) for adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior lines of treatment, including prior Avastin (bevacizumab).
The approval follows last month’s FDA approval of Keytruda (pembrolizumab) with weekly Taxol (paclitaxel) for platinum-resistant ovarian cancer. While the combination of Keytruda with weekly Taxol is limited to patients with PD-L1-positive tumors, the combination ofLifyorli with weekly Abraxane requires no biomarker testing to determine eligibility.
The FDA’s approval of Lifyorli in combination with nab-paclitaxel is welcome news to all of us in the ovarian cancer community,” said Sarah DeFeo, Chief Program Officer at OCRA, in a press release from Corcept Therapeutics. “We are grateful to everyone who participated in the clinical trials, their families and the physicians who helped advance this urgently needed treatment option for patients with platinum-resistant ovarian cancer.
How Lifyorli Works
Lifyorli is the first FDA-approved drug of its kind for ovarian cancer. It works by blocking cortisol, a stress hormone, from helping cancer cells resist chemotherapy.
Lifyorli is taken as a pill on the day before, the day of, and the day after each Abraxane infusion. Results from the phase 3 ROSELLA trial showed the combination improved both progression-free and overall survival compared to Abraxane alone. In clinical trials, adding Lifyorli did not add any new significant side effects beyond those of Abraxane alone.
For patients and families with questions about this approval, your care team is the best resource for what it may mean for your individual treatment plan.
–
Note: This article is intended to share research and regulatory news. It is not medical advice. Patients should speak with their healthcare team about individual treatment decisions.
